These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 9261609)
21. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy. Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855 [TBL] [Abstract][Full Text] [Related]
22. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA. Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994 [TBL] [Abstract][Full Text] [Related]
23. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617 [TBL] [Abstract][Full Text] [Related]
24. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer]. Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205 [TBL] [Abstract][Full Text] [Related]
25. [Value of serum CA 19-9 determination in the diagnosis of pancreatic carcinoma]. Pei DP Zhonghua Wai Ke Za Zhi; 1990 Oct; 28(10):625-7, 638-9. PubMed ID: 2086060 [TBL] [Abstract][Full Text] [Related]
26. [Urine diacetylspermine as a novel tumor marker for pancreatobiliary carcinomas]. Yamaguchi K; Nagano M; Torada N; Hamasaki N; Kawakita M; Tanaka M Rinsho Byori; 2004 Apr; 52(4):336-9. PubMed ID: 15164602 [TBL] [Abstract][Full Text] [Related]
27. Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients. Torzilli G; Makuuchi M; Ferrero A; Takayama T; Hui AM; Abe H; Inoue K; Nakahara K Hepatogastroenterology; 2002; 49(45):740-5. PubMed ID: 12063982 [TBL] [Abstract][Full Text] [Related]
28. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases. Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469 [TBL] [Abstract][Full Text] [Related]
30. [Significance of detection of K-ras gene mutations and CA19-9 in serum for diagnosis of pancreatic carcinoma]. Zhang Y; Ji SR; Feng DX; Ji J; Han TQ Ai Zheng; 2003 Mar; 22(3):295-7. PubMed ID: 12654190 [TBL] [Abstract][Full Text] [Related]
31. The effect of colonoscopy on tumor markers. Scapa E; Broide E; Pinhasov I Surg Laparosc Endosc; 1997 Dec; 7(6):477-9. PubMed ID: 9438630 [TBL] [Abstract][Full Text] [Related]
32. Improved sensitivity of fuzzy logic based tumor marker profiles for diagnosis of pancreatic carcinoma versus benign pancreatic disease. Halm U; Rohde N; Klapdor R; Reith HB; Thiede A; Etzrodt G; Mössner J; Keller T Anticancer Res; 2000; 20(6D):4957-60. PubMed ID: 11326646 [TBL] [Abstract][Full Text] [Related]
33. Elevated tumor marker CA 19-9 in the differential diagnosis of pancreatic mass lesions. Cwik G; Wallner G; Skoczylas T; Krzyzanowski M; Ciechainski A; Madro P Ann Univ Mariae Curie Sklodowska Med; 2004; 59(2):213-8. PubMed ID: 16146081 [TBL] [Abstract][Full Text] [Related]
34. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice. Ng WW; Tong KJ; Tam TN; Lee SD Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181 [TBL] [Abstract][Full Text] [Related]
35. Limits of CEA and ferritin in the diagnosis of pancreatic cancer. Plebani M; Fabris C; Basso D; Del Favero G; Angonese C; Leandro G; Di Mario F; Burlina A; Naccarato R Int J Pancreatol; 1988; 3 Suppl 1():S113-7. PubMed ID: 3209864 [TBL] [Abstract][Full Text] [Related]
36. The use of tumor markers as predictors of prognosis in gastric cancer. Mihmanli M; Dilege E; Demir U; Coskun H; Eroglu T; Uysalol MD Hepatogastroenterology; 2004; 51(59):1544-7. PubMed ID: 15362797 [TBL] [Abstract][Full Text] [Related]
37. Role of cystic fluid in diagnosis of the pancreatic cystadenoma and cystadenocarcinoma. Wu H; Yan LN; Cheng NS; Zhang YG; Ker CG Hepatogastroenterology; 2007; 54(79):1915-8. PubMed ID: 18251127 [TBL] [Abstract][Full Text] [Related]
38. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014 [TBL] [Abstract][Full Text] [Related]
39. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Marrelli D; Caruso S; Pedrazzani C; Neri A; Fernandes E; Marini M; Pinto E; Roviello F Am J Surg; 2009 Sep; 198(3):333-9. PubMed ID: 19375064 [TBL] [Abstract][Full Text] [Related]
40. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. Okusaka T; Okada S; Sato T; Wakasugi H; Saisho H; Furuse J; Ishikawa O; Matsuno S; Yokoyama S Hepatogastroenterology; 1998; 45(21):867-72. PubMed ID: 9684148 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]